Entries by Hanna Frykman

SenzaGen approved for trading on Nasdaq First North

THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET SenzaGen AB (“SenzaGen” or “the Company”) has today been approved by Nasdaq Stockholm AB as an issuer of shares on Nasdaq First North in Stockholm. The first trading day […]

SenzaGen’s share offer heavily oversubscribed prior to listing on Nasdaq First North

THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET The offer of shares in SenzaGen AB (“SenzaGen” or “the Company”) prior to the Company’s listing on Nasdaq First North was heavily oversubscribed. The Company expects to raise SEK […]

New colleague at SenzaGen

Welcome to SenzaGen Henrik Appelgren! Henrik has started his position as Chief Scientific Officer with us here at SenzaGen this week. Henrik is a biologist with a PhD in genetic toxicology. He has been working at the Swedish Chemicals Agency for 15 years, where he worked as Sweden’s national coordinator in the OECD Test Guideline […]

SenzaGen is presenting at hosted session at the EUROTOX Congress in Bratislava

SenzaGen new Chief Scientific officer Hernik Appelgren will give a presentation on 21st century testing for skin sensitisation and updates on application of the GARD platform at The 53rd  European Congress of the European Societies of Toxicology, EUROTOX, on the 12th of Sept. SenzaGen is also Exhibiting at the congress and presenting two posters The […]

Integrated hazard identification of chemical sensitizers using in vitro and in silico readouts – A comparative evaluation of predictive performance

By Lhasa Donna Macmillan, Henrik Johansson, Olivia Larne, Malin Lindstedt 1. Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS 2. SenzaGen, Lund, Sweden 3. Lund University, Lund, Sweden   Introduction There has been a significant drive to reduce, refine and replace animal models for the prediction of skin sensitization. This is in part due […]

New colleague at SenzaGen

Welcome to SenzaGen Anna Chérouvrier Hansson! Anna has started her position as Chief Commercial Officer with us here at SenzaGen this week. Anna comes from Camurus, a pharmaceutical company developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions. At Camurus, Anna was Director of Marketing and responsible for the […]

Skin Sensitization: Challenging the Conventional Thinking – A Case Against 2 Out of 3 as Integrated Testing Strategy

Toxicological Sciences, Volume 159, Issue 1, 1 September 2017, Pages 3–5, https://doi.org/10.1093/toxsci/kfx115 Published: 27 June 2017 Henrik Johansson,  Robin Gradin Background Recent years have seen a surge in development of alternative methods for assessment of skin sensitizers. This has been in order to meet the regulatory and industrial demand for accurate safety assessment without the use […]

Performance of the GARD assay in a blind Cosmetics Europe study

Johansson H, Gradin R, Forreryd A, Agemark M, Zeller K, Malmborg-Hager A1, Johansson A, Larne O, Van Vliet E3, Borrebaeck C, Lindstedt M, SenzaGen AB, Lund, Sweden, Department of Immunotechnology, Lund University, Lund, Sweden, Cosmetics Europe –The Personal Care Association, Brussels, Belgium Introduction Chemical hypersensitivity is an immunological response to foreign substances. Primarily, these give […]